$52.41 2.7%
CRNX Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors.


Crinetics Pharmaceuticals
Price $52.41
Target Price Sign up
Volume 737,180
Market Cap $4.34B
Year Range $26.93 - $54.98
Dividend Yield 0%
Revenue per Employee $6,962
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24130,00021M-21M-67M-73M0.000
Q4 '23017M-22M-60M-62M-0.900
Q3 '23350,00015M-15M-57M-59M-1.010
Q2 '23990,00013M-12M-51M-53M-0.940
Q1 '232.7M12M-9.8M-46M-48M-0.850

Insider Transactions View All

Wilson Marc filed to sell 111,092 shares at $55.
July 17 '24
Knight Jeff E. filed to sell 51,653 shares at $55.
July 17 '24
Betz Stephen F. filed to sell 78,611 shares at $48.6.
July 12 '24
Hassard James filed to sell 29,259 shares at $44.1.
July 9 '24
Pizzuti Dana filed to sell 28,507 shares at $44.9.
July 5 '24

What is the Market Cap of Crinetics Pharmaceuticals?

The Market Cap of Crinetics Pharmaceuticals is $4.34B.

How Many People Work at Crinetics Pharmaceuticals?

As of our latest update, Crinetics Pharmaceuticals employed approximately 210 people worldwide. However, it's important to note that Crinetics Pharmaceuticals' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Crinetics Pharmaceuticals' revenue per employee?

$6,962. To calculate Crinetics Pharmaceuticals' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Crinetics Pharmaceuticals?

Currently, the price of one share of Crinetics Pharmaceuticals stock is $52.41.

How can I analyze the CRNX stock price chart for investment decisions?

The CRNX stock price chart above provides a comprehensive visual representation of Crinetics Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Crinetics Pharmaceuticals shares. Our platform offers an up-to-date CRNX stock price chart, along with technical data analysis and alternative data insights.

Does CRNX offer dividends to its shareholders?

As of our latest update, Crinetics Pharmaceuticals (CRNX) does not offer dividends to its shareholders. Investors interested in Crinetics Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Crinetics Pharmaceuticals?

Some of the similar stocks of Crinetics Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.